1. A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection 
Kuo-Chin Chang, Po-Lin Tseng, Yi-Ying Wu, Hung-Chao Hung, Chao-Min Huang, Sheng-Nan Lu, Jing-Houng Wang, Chuan-Mo Lee, Chien-Hung Chen, Ming-Chao Tsai, Yi-Hao Yen, Ming-Tsung Lin, Cheng-Kun Wu, Chao-Cheng Huang, Hsiu-Hsi Chen, Tsung-Hui Hu 
Clinical Gastroenterology and Hepatology 
Volume 13, Issue 5, Pages (May 2015)
DOI: /j.cgh
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier analysis of the incidence of hepatocellular carcinoma in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin by patient characteristic. F, fibrotic stage; G1, HCV genotype 1; PLT, platelet count.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
Kaplan–Meier analysis of the cumulative incidence of hepatocellular carcinoma in chronic hepatitis C patients after antiviral therapy (A) without and (B) with sustained viral response by IL28B rs genotype.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2015 AGA Institute Terms and Conditions